



Center for Vaccine Ethics & Policy (CVEP)
Vaccines and Global Health: The Week in Review
14 February 2026 :: Issue 832

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

*David R. Curry, MS
Editor and
Executive Director Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org*

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

:::::::
:::::::

Pandemic Accord – PABS Mechanism

Editor's Note:

The IGWG closed its fifth meeting today, with the closing two segments live-streamed as noted below. No transcript of the WHO DG's closing remarks or the PABS text as it stood at the close of the meeting was posted as we published this edition. Viewers of the closing sessions will note the candor of a number of delegations regarding progress made during the sessions.

[Fifth meeting of the Intergovernmental Working Group \(IGWG\) on the WHO Pandemic Agreement](#)

9 – 14 February 2026
Hybrid, Geneva, Switzerland
A/IGWG/5/1
Provisional agenda
A/IGWG/5/2
Draft programme of work
Draft PABS Annex text

IGWG5 - Session 1

Item 1 - Opening of the session and adoption of the agenda and programme of work
09/02/2026 - 09:05-10:29
Includes WHO DG opening remarks.

IGWG5 - Item 5 & 6 - Report of the meeting & Closure of the session

14/02/2026 - 15:30-16:10
Includes WHO DG closing remarks.

IGWG Meeting timeline

- 9–10 July 2025: First meeting of the IGWG
- 15–19 September 2025: Second meeting of the IGWG
- Week of 6–10 October 2025: Informal meetings of the IGWG
- 3–7 November 2025: Third meeting of the IGWG
- 24–25 November 2025: Informal dialogues of the IGWG
- 1–5 December 2025: Fourth meeting of the IGWG
- **9–14 February 2026: Fifth meeting of the IGWG**
- 23–28 March 2026: Sixth meeting of the IGWG
- July 2026 (tbc): Seventh meeting of the IGWG
- September 2026 (tbc): Eighth meeting of the IGWG

:::::::
:::::::

IA2030 – WHO EB Review

[WHO's Executive Board reviews progress on Immunization Agenda 2030](#)

10 February 2026 *Departmental update*

[Excerpt]

...Member States underscored the importance of country ownership. Aligning IA2030 with national plans, strengthening domestic financing, and ensuring sustainability pathways were seen as essential to achieving long-term immunization goals.

Looking ahead, Member States stressed that IA2030 will require sharper focus and stronger action from WHO and its partners, including Gavi, UNICEF, the Global Fund, and civil society. Member States asked WHO to provide clear prioritization guidance for the second half of the IA2030 decade, ensuring that limited resources are directed toward the most critical areas, and **called on the Organization to take the lead in sustaining demand for immunization through evidence-based guidance and coordinated partner action.**

The IA2030 mid-term review will be discussed by all Member States at the seventy-ninth World Health Assembly in May 2026.

Additionally, **Member State discussions on the End TB Strategy and the Polio Eradication Strategy also stressed the need to sustain commitment and financing. Member States warned that the world is off track to meet End TB milestones** and called for stronger integration of TB services into primary health care, equitable access to diagnostics and treatments, and innovation, including new TB vaccines for adolescents and adults.

While Member States welcomed progress in interrupting wild poliovirus transmission outside limited areas of Afghanistan and Pakistan, **they stress the need for intensified efforts to reach zero-dose and mobile populations.** They emphasized trust-building, strong routine immunization and surveillance, and partner collaboration. **Member States supported the extension of the Polio Eradication Strategy to 2029** and the integration of polio assets into broader health systems for long-term resilience.

:::::::

:::::::

Africa – Local Manufacturing

Communiqué

Presidential Declaration on Advancing Local Manufacturing of Health Products in Africa

14 February 2026

On the margins of the 39th Ordinary Session of the Assembly of the African Union

We, the Heads of State and Government, Ministers of Health of AU member states High-Level Representatives, and Partners

- Recalling the Assembly Decisions Assembly/AU/Dec.877(XXXVII) and Assembly/AU/Dec.924(XXXVIII) on advancing health products manufacturing, pooled procurement, and regulatory harmonization.
- **Recognizing local manufacturing of pharmaceuticals, vaccines, diagnostics, and medical devices as a strategic pillar for Africa's health security and sovereignty agenda.**
- Acknowledging the leadership of Africa CDC in advancing the Platform for Harmonized African Health Products Manufacturing and operationalizing the African Pooled Procurement Mechanism (APPM);
- **Reaffirming the continental ambition to meet at least 60 percent of Africa's health product needs through local manufacturing by 2040;**

We hereby declare our commitment to:

1. Advance local manufacturing of health products as a continental priority for health security and sovereignty
2. Support the **full operationalisation of the African Pooled Procurement Mechanism as a strategic “Buy African” tool** through demand aggregation, market shaping, long-term offtake arrangements in order to increase access to quality-assured health products and promote predictable and sustainable markets for African manufacturers.
3. **Mobilise sustainable and appropriate financing for local manufacturers** including the establishment of the APPM capital fund.
4. Increase investments to enhance skills development, innovation and technology transfer through partnerships and operationalisation of the Africa CDC Regional Capacity and Capability Networks.
5. **Express strong support for the convening of an Extraordinary Summit on African Health Products Manufacturing in Nairobi, Kenya in Q2 2026**, chaired by H.E. President William Samoei Ruto, President of the Republic of Kenya, AU Champion on Local Manufacturing, and co-hosted by the Africa CDC, **to accelerate implementation, endorse concrete commitments, and demonstrate sustained political leadership.**

Adopted on 14 February 2026 in Addis Ababa, Ethiopia on the margins of the 39th AU Summit

:::::::

:::::::

Guinea-Bissau Trial

Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau

13 February 2026 Statement Geneva

The World Health Organization (WHO) underscores that the hepatitis B birth dose vaccine is an effective, and essential public health intervention, with a proven record. It prevents life-threatening liver disease by stopping mother-to-child transmission at birth. It has been used for over three decades, with more than 115 countries including it in their national schedules. Protecting newborns with a timely birth dose not only provides individual benefit but is also central to national and global elimination efforts.

In response to recent questions from the media, WHO would like to state the following:

WHO is aware of the proposed randomized controlled trial (RCT) on the hepatitis B birth dose vaccine in Guinea-Bissau. Based on questions raised in publicly available information and consultation with relevant experts, **WHO has significant concerns regarding the study's scientific justification, ethical safeguards, and overall alignment with established principles for research involving human participants.**

Why withholding the vaccine is unethical

- **Proven benefit, foreseeable harm:** The hepatitis B birth dose vaccine is known to have a proven safety record across decades of use and is effective in preventing 70–95% of cases of mother-to-child transmission. A study which provides the hepatitis B birth dose vaccine, a proven lifesaving intervention, but withholds it from some study participants exposes newborns to serious and potentially irreversible harm, including chronic infection, cirrhosis, and liver cancer.
- **No scientific necessity for a no-treatment arm:** Placebo or no-treatment vaccine trials are only acceptable when no proven intervention exists or when such a design is indispensable to answer a critical question of efficacy or safety. Neither condition appears to be met based on publicly available descriptions of the study.
- **Insufficient scientific justification:** Publicly available descriptions indicate that the protocol does not question the established efficacy and impact of the birth dose; instead, it posits hypothetical

safety outcomes without sufficient credible evidence of a safety signal that would warrant exposing participants to risk.

- **Biased and low-utility design:** As described publicly, the single-blind, no-treatment-controlled design raises a significant likelihood of substantial risk of bias, limiting interpretability of the study results and their policy relevance.
- **Exploiting scarcity is not ethical:** Resource constraints cannot be used to justify withholding proven care in a research study involving people. Ethical obligations require minimizing risk and ensuring a prospect of benefit for participants. From what is publicly described, the protocol does not appear to ensure even a minimum level of harm reduction and benefit to the study participants (e.g. screening pregnant women and vaccinating newborns exposed to hepatitis B).

In its current form, and based on publicly available information, the trial is inconsistent with established ethical and scientific principles.

WHO is aware that Guinea-Bissau has suspended the study pending further technical reviews. WHO stands ready to support Guinea-Bissau as it considers its way forward and in accelerating the introduction of the birth dose and strengthening implementation through:

- birth-dose delivery within 24 hours (including strategies for home and facility births);
- antenatal screening for hepatitis B surface antigen (HBsAg), linkage to care, and neonatal prophylaxis;
- cold-chain, last-mile logistics, and midwife/HCW training; and
- monitoring of timeliness and coverage, pharmacovigilance, and data use for continuous improvement.

WHO remains committed to working with national authorities, researchers, and partners to ensure that all newborns – in Guinea-Bissau and worldwide – receive timely, evidence-based protection against hepatitis B, and that research conducted in this area meets the highest ethical and scientific standards.

Editor's note

Hepatitis B causes hundreds of thousands of deaths globally each year. Transmission at birth is the most common route to lifelong infection; ~90% of newborns infected during childbirth become chronic carriers at high risk of cirrhosis and liver cancer.

In Guinea-Bissau, >12% of adults are estimated to be living with chronic hepatitis B (2022), and infection in children under five (~2% in 2020) is far above the global target ($\leq 0.1\%$). Guinea-Bissau formally decided in 2024 to add the hepatitis B birth dose to its national schedule, with introduction planned by 2028. This policy decision affirms the vaccine's value and further underscores the ethical imperative not to deny newborns timely protection.

:::::::

Notice of Award of a Single Source Unsolicited Grant To Fund University of Southern Denmark (SDU)

A Notice by the Centers for Disease Control and Prevention on 12/18/2025

SUMMARY:

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$1,600,000 over a five-year period, in response to an unsolicited proposal that has been submitted by University of Southern Denmark (SDU). The award will support a comparable study of the optimal timing and delivery of monovalent Hepatitis B vaccinations on newborns in Guinea-Bissau. Activities will include conducting a randomized controlled trial to assess the effects of neonatal Hepatitis B vaccination on early-life mortality, morbidity, and long-term developmental outcomes. The award is in response to an unsolicited proposal.

SUPPLEMENTARY INFORMATION:

The proposed work being funded will support a single-blind, multi-center, phase IV randomized controlled trial enrolling over 14,000 neonates in Guinea-Bissau to evaluate the impact of neonatal monovalent Hepatitis B vaccination (HBV0) on all-cause mortality, severe morbidity, and long-term developmental outcomes. The study will also assess potential sex-differential effects of the vaccine. While the World Health Organization (WHO) recommends three vaccines at birth in low-income settings—Bacille Calmette Guérin (BCG), oral polio vaccine (OPV0), and HBV0—there is limited evidence on the broader health effects of HBV0. This study aims to fill that gap by rigorously evaluating the overall health impact of HBV0 in early life.

CDC performed an objective review of the proposed work and determined, in accordance with its process for reviewing unsolicited proposals that the proposal has merit and that SDU is in a unique position to conduct this work, as it has extensive experience conducting vaccine trials in West Africa, established partnerships with local hospitals and health authorities in Guinea-Bissau, and a proven track record in neonatal and pediatric research in low-resource settings.

The award is being made non-competitively because there is no current, pending, or planned funding opportunity announcement under which this proposal could compete.

Summary of the Award

:: Recipient: University of Southern Denmark (SDU).

:: Purpose of the Award: The purpose of this award is to evaluate the effects of neonatal monovalent Hepatitis B vaccination (HBV0) on early-life mortality and morbidity, as well as long-term neurodevelopmental outcomes, through a randomized controlled trial in Guinea-Bissau.

The findings will inform global immunization policy and practice, particularly regarding the broader health effects of HBV0, which remain less well understood compared to BCG and OPV0.

:: Amount of Award: \$1,600,000 in Federal Fiscal Year (FFY) 2026 funds, with the total estimated \$1,600,000 provided for the full five-year period of performance, subject to availability of funds.

:::::::
:::::::
:::::::

Polio – PHEIC

[Polio this week](#) [11 Feb 2026]

Headlines [Selected]

:: The Government of Japan, through the Japan International Cooperation Agency (JICA), has provided US\$6.3 million to UNICEF to renew its partnership on polio eradication and strengthen routine immunization across all 34 provinces of Afghanistan. The 12-month initiative aims to reach over 12 million children under five with lifesaving polio vaccines for supplementary immunization activities and routine immunization services. [Read more...](#)

Summary of new polioviruses this week:

:: Pakistan: eight WPV1-positive environmental samples

:: Somalia: one cVDPV2 case and two cVDPV2-positive environmental samples

:::::::

WHO prequalifies an additional novel oral polio vaccine, strengthening global outbreak response

13 February 2026 Departmental update

The World Health Organization (WHO) has **prequalified an additional novel oral polio vaccine type 2 (nOPV2)**, further strengthening the global supply of a vaccine at the heart of efforts to stop poliovirus type 2 outbreaks more sustainably and accelerate progress towards polio eradication.

The prequalification designation indicates that the vaccine meets international standards of quality, safety, and efficacy for global immunization programmes. It enables the vaccine to be purchased and supplied through United Nations procurement agencies, including UNICEF, supporting its use across multiple country settings for the prevention and control of poliovirus transmission.

The newly prequalified product is manufactured by Biological E. Limited (BioE), India, using in-house bulk vaccine following a technology transfer from PT Bio Farma (Persero), Indonesia. This prequalification builds on earlier WHO listings of nOPV2 manufactured by PT Bio Farma, as well as the vaccine formulated and filled by BioE using bulk supplied by PT Bio Farma.

With this latest addition, WHO continues to diversify and strengthen the manufacturing base for quality-assured nOPV2, helping to ensure a more resilient, reliable and sustainable vaccine supply for countries responding to outbreaks...

:::::::
:::::::

Obituary

Alan Hinman

March 23, 1937 — January 26, 2026



[Excerpts: Full obituary: <https://www.asturner.com/obituaries/alan-hinman>]

After 88 years of an extraordinary life, Dr. Alan R. Hinman has shuffled off this mortal coil, run down the curtain, and joined the choir invisible, passing away on Monday, January 26, 2026...

Alan earned his undergraduate degree from Cornell University, his medical degree from Western Reserve University, and a Master of Public Health from Harvard University. Beginning in 1965 with his training in the Epidemic Intelligence Service, he devoted his life to public health at the state, national, and international levels, including the Centers for Disease Control and Prevention (CDC), where he served as Director of the Immunization Division (1977-1988) and later Director of the National Center for Prevention Services (1988-1995). He also worked with the state health departments of New York and Tennessee, rose to the rank of Assistant Surgeon General, and after retiring from governmental public health service joined The Task Force for Global Health in 1996. Alan authored or coauthored

more than 400 publications, served on the board of Gavi, the Vaccine Alliance, and chaired a WHO advisory committee. In his later years, he continued teaching and mentoring as an adjunct professor of Global Health and Epidemiology at the Rollins School of Public Health at Emory University...

If you knew Alan professionally, you likely knew him as a public health leader through and through, brilliant, persistent, and unusually gifted at making complex issues understandable without making people feel small. Colleagues recall his unmatched communication skills and his legendary editing. One longtime collaborator fondly remembers Alan's orange ink pen, nicknamed "Agent Orange" a title bestowed by others, not Alan, as it went to work immunizing draft after draft against confusion, one sharply chosen phrase at a time. Alan played a major role in advancing the first Presidential Initiative on Immunization during the Carter Administration, encouraging states to enact and enforce school immunization mandates to prevent outbreaks of vaccine preventable disease. His work helped reduce suffering in the United States and around the world, including critical contributions toward polio eradication and measles elimination efforts. Alan didn't just talk about protecting communities, he helped build the systems that actually did it.

Alan also served the American Public Health Association with deep devotion, including many years on the Executive Board and 11 years as Speaker of the Governing Council (1996-2007). During his tenure, the Governing Council experienced meaningful growth and modernization, including standing rules that continue to guide the Association and the further formalization of the policy statement process. Alan took special pride in what the family affectionately called the Hinman APHA connection, now spanning four generations, and in the delightfully improbable achievement of perhaps being the first family to hold three simultaneous seats on the Governing Council, each representing a different unit. He was especially proud of the leadership of his daughter Johanna Hinman and his daughter in law, Lisa Carlson (APHA Past President), both of whom have strengthened the Association with their own tireless service...

A memorial celebration is being planned for a later date.

:::::::

Contents [click to move among sections]

- [:: Milestones, Perspectives](#)
- [:: WHO](#)
- [:: U.S. Immunization and Public Health Governance/Policy/Funding](#)
- [:: Organization Announcements](#)
- [:: Journal Watch](#)
- [:: Pre-Print Servers](#)
- [:: Think Tanks](#)
- [:: Public Consultations/Call for Inputs/Call for Papers](#)

:::::::

:::::::

WHO & Regional Offices [14 Feb 2026]

<https://www.who.int/news>

Selected News/Announcements/Statements

13 February 2026 *Statement*

[**Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau**](#)

13 February 2026 *Departmental update*

[**WHO prequalifies an additional novel oral polio vaccine, strengthening global outbreak response**](#)

12 February 2026 *Departmental update*

Partners discuss improving pooled procurement of emergency medical countermeasures

12 February 2026 *Departmental update*

WHO launches landmark consolidated operational handbook to strengthen the global STI response amid rising infections

10 February 2026 *Departmental update*

WHO's Executive Board reviews progress on Immunization Agenda 2030

:::::::

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1

News

13 February 2026 *Statement*

Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau

10 February 2026 *Departmental update*

WHO's Executive Board reviews progress on Immunization Agenda 2030

:::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

Website not responding at inquiry.

WHO Region of the Americas PAHO

:: 13 Feb 2026

PAHO and CARPHA sign landmark 2026-2030 framework agreement to strengthen regional health collaboration

Port of Spain, Trinidad and Tobago, 13 February 2026.- The Pan American Health Organization (PAHO) and the Caribbean Public Health Agency (CARPHA) formalised their continued partnership with the signing of the 2026–2030 Framework Agreement, reinforcing a shared commitment to advancing public health priorities across the Caribbean. The...

:: 12 Feb 2026

PAHO and SJD Barcelona Children's Hospital promote network to expand access to hematopoietic transplantation for children with Cancer in the Andean region

Washington, D.C., February 12, 2026 (PAHO) – More than 160 health professionals from the Andean subregion are collaborating on a project to strengthen capacity for pediatric cancer care, with a special focus on pediatric hematopoietic transplantation (HT) in their region. This initiative is part of a cooperation agreement signed between the Pan...

:: 11 Feb 2026

Chikungunya cases increasing in several countries in the Americas; PAHO recommends preparedness

Washington, D.C., February 11, 2026 (PAHO) — The Pan American Health Organization (PAHO) has issued an epidemiological alert following a sustained increase in chikungunya cases in several countries in the Americas since late 2025 and into early 2026. The alert also highlights the re-emergence of local transmission in areas that had not reported...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: [**Measles cases dropped in Europe and Central Asia in 2025 compared to the previous year, but the risk of outbreaks remains – UNICEF and WHO**](#)

11 February 2026

WHO Eastern Mediterranean Region EMRO

:: [**Pakistani hospitals preparing for arrival of free childhood cancer medicines in 2026 under WHO-Pakistan agreement**](#)

12 February 2026

:: [**World Health Organization appeals for urgent health funding to protect millions of lives in Yemen in 2026**](#)

12 February 2026

:: [**Mobilizing 400,000 WHO-trained polio workers to vaccinate 45 million children in Pakistan**](#)

11 February 2026

WHO Western Pacific Region

:: 12 February 2026

[**Brunei Darussalam strengthens One Health collaboration through zoonotic disease prioritiza...**](#)

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[**14 February 2026 | Mpox: recombinant virus with genomic elements of clades Ib and IIb - Global**](#)

Recombination of monkeypox virus (MPXV) strains has been documented in recent months, with two cases of a recombinant strain comprising clade Ib and IIb MPXV reported

::::::

Weekly Epidemiological Record

Vol. 101, No. 7 13 February 2026

<https://iris.who.int/server/api/core/bitstreams/76f8278b-2074-4836-a36c-6c7372b6d927/content>

::: Summary of the Fortieth Meeting of the International Task Force for Disease Eradication (ITFDE) October 28-29, 2025

::::::

New WHO Publications

<https://www.who.int/publications>

Selected

13 February 2026

Summary of the Fortieth Meeting of the International Task Force for Disease Eradication (ITFDE) October...

12 February 2026

The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use...

11 February 2026

WHO consolidated operational handbook on sexually transmitted infections

11 February 2026

Independent External Review of EPI-VPD surveillance in Thailand, 1-8 September 2025

11 February 2026

Subnational implementation review workshop of the Big Catch-Up (BCU) immunization initiative in priority countries of the WHO South-East Asia Region

8 February 2026

Report of the eighteenth annual meeting of the Global Alliance against Chronic Respiratory Diseases:...

:::::::

:::::::

:::::::

Africa

Africa CDC [14 Feb 2026]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Communiqué

Presidential Declaration on Advancing Local Manufacturing of Health Products in Africa

14 February 2026

Press Releases

UNFPA and Africa CDC Forge Strategic Partnership to Advance Health and Innovation

Across Africa

12 February 2026

:::::::

:::::::

China – CDC+

National Health Commission of the People's Republic of China [14 Feb 2026]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [14 Feb 2026]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2026-02-13 / No. 7

[PDF of this issue](#)

:: [Outbreak Reports: A Local Chikungunya Fever Outbreak Field Investigation — Fujian Province, China, 2025](#)

:: [Outbreak Reports: First Human Case of Streptococcus parasuis Infection — Henan Province, China, 2025](#)

:: [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, December 2025*](#)

::::::

::::::

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[**Community spread drives ongoing measles transmission in Europe**](#)

9 Feb 2026

Preliminary data for 2025 show a significant drop in the number of reported measles cases across European Union and European Economic Area (EU/EEA) countries compared with 2024. However, these figures are still twice as high than those reported in 2023. As the number of measles infections typically peaks during late winter and early spring, now is the time for everyone to check their measles vaccination status.

Surveillance and monitoring

[**Communicable disease threats report, 7 - 13 February 2026, week 7**](#)

13 Feb 2026

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 February 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, mass gathering monitoring, avian influenza, chikungunya, dengue, Nipah virus disease, and measles.

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

::::::

::::::

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare

Announcements

No new digest content identified.



U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive

Executive Branch - White House, State, HHS, FDA, CDC+

White House

[Presidential Actions – Executive Orders; Memoranda; Proclamations](#)
No new digest content identified.

Department of State

[Press Releases - Selected](#)
No new digest content identified.

HHS

[Press Room - Selected](#)
[Secretary Kennedy Enhances Management Team to Accelerate President Trump's Priorities and MAHA Agenda](#)

February 12, 2026 *Press Release*

Today, Secretary Robert F. Kennedy, Jr. announced several enhancements to his management team at the U.S. Department of Health and Human Services (HHS) to accelerate adoption of President Trump's Great Healthcare Plan and the Make America Healthy Again agenda.

As part of these changes, Chris Klomp will become Chief Counselor at HHS and oversee all operations of the Department. Chris brings decades of management and leadership experience to the role. In addition, Secretary Kennedy has named Kyle Diamantas and Grace Graham as Senior Counselors for the Food and Drug Administration (FDA) and John Brooks as Senior Counselor for the Centers for Medicare & Medicaid Services (CMS). Each of these individuals will continue to serve in their current roles in addition to serving in Secretary Kennedy's office.

"In just over a year, we have driven historic progress on President Trump's health care priorities and delivered real, measurable change," said Secretary Kennedy. "We are restoring accountability, challenging entrenched interests, and putting the health of the American people first. I am proud to elevate battle-tested, principled leaders onto my immediate team—individuals with the courage and experience to help us move faster and go further as we work to Make America Healthy Again."

NIH [to 14 Feb 2026]

<http://www.nih.gov/>

News Releases

No new digest content identified.

FDA

[Press Announcements](#)

[FDA News Releases](#)

No new digest content identified.

FDA CBER

What's New for Biologics
No new digest content identified.

[**Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010**](#)

:: Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has requested a Type A meeting to understand the path forward

:: mRNA-1010 has been submitted and accepted for review in the EU, Canada and Australia

:: Company does not expect any impact on its 2026 financial guidance

February 10, 2026

..."This decision by CBER, which did not identify any safety or efficacy concerns with our product, does not further our shared goal of enhancing America's leadership in developing innovative medicines," said Stéphane Bancel, Chief Executive Officer of Moderna. "It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting. We look forward to engaging with CBER to understand the path forward as quickly as possible so that America's seniors, and those with underlying conditions, continue to have access to American-made innovations."

Moderna has requested a Type A meeting with CBER to understand the basis for the RTF letter. In the interest of transparency, the Company has posted the full letter on its website, [linked here...](#)

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

[**Vaccines and Related Biological Products Advisory Committee - March 12, 2026**](#)

On March 12, 2026, the Committee will meet in open session to discuss and make recommendations on the strain composition of influenza virus vaccines for use in United States during the 2026-2027 influenza season

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

No future meetings posted.

CDC

<http://www.cdc.gov/media/index.html>

Latest News - Selected

No new digest content identified.

CDC – Immunization Safety Office (ISO)

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

No new digest content identified.

ACIP

2026 Meetings Schedule

- **February 25-26** *[no agenda content posted]*
- June 24-25
- October 21-22

National Vaccine Advisory Committee (NVAC)

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

No new digest content identified.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

No new digest content identified.

:::::::

NSF

News

No new digest content identified.

:::::::

U.S. Congress**House of Representatives**

No new digest content identified.

U.S. Senate**Senate Health, Education, Labor, and Pensions (HELP) Committee**

No new digest content identified.

:::::::

Supreme Court, Federal & Appellate Courts

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

No new digest content identified.

:::::::

:::::::

:::::::

U.S. Medical, Professional Societies; Health Organizations

This inventory is evolving and may not capture all instances of relevant comment and analysis.

American Academy of Family Physicians (AAFP)

<https://www.aafp.org/news/media-center.html>

(Accessed 14 Feb 2026)

No new digest content identified.

American Academy of Pediatrics (AAP)

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 14 Feb 2026)

News

No new digest content identified.

American College of Physicians (ACP)

<https://www.acponline.org/more-acp-news>

(Accessed 14 Feb 2026)

ACP News

No new digest content identified.

America's Health Insurance Plans (AHIP)

<https://www.ahip.org/news>

(Accessed 14 Feb 2026)

News

No new digest content identified.

American Geriatrics Society (AGS)

<https://www.americageriatrics.org/media-center>

(Accessed 14 Feb 2026)

Recent Press Releases

No new digest content identified.

American Medical Association (AMA)

<https://www.ama-assn.org/press-center>

(Accessed 14 Feb 2026)

Press Releases

Feb 10, 2026 · 4 MIN READ

[AMA, Vaccine Integrity Project launch vaccine review for next respiratory season](#)

MINNEAPOLIS, Minn. — The Vaccine Integrity Project, in collaboration with the American Medical Association (AMA), today announced **the kickoff of a structured, evidence-based review process to assess vaccine safety and effectiveness for the 2026–27 respiratory virus season. The review will focus on immunizations for influenza, COVID-19, and respiratory syncytial virus (RSV).**

Building on the thorough evidence review completed for the 2025–26 season, **this new effort will establish a structured and durable process for evaluating the science underpinning respiratory virus immunization**. The Vaccine Integrity Project, based at the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP), and the AMA will convene leading medical professional societies as well as public health and health care organizations to help define a comprehensive set of policy questions. **The goal of this work is to ensure a deliberative, evidence-driven approach to produce the data necessary to understand the risks and benefits of vaccine policy decisions for all populations—the approach traditionally used by the federal government.**

"Respiratory viruses hospitalize and kill tens of thousands of Americans every year, and vaccine decisions must be guided by facts, not politics or ideology," said CIDRAP Director Michael Osterholm, PhD, MPH. "Our goal is to build on our efforts to restore peace of mind for clinicians and patients by

ensuring that experts are continuously evaluating vaccine safety and effectiveness using transparent, evidence-based methods."

For decades, the Centers for Disease Control and Prevention's **Advisory Committee on Immunization Practices (ACIP) served as the engine of evidence-based vaccine policy in the United States. That system has now effectively collapsed.** This new initiative will follow a rigorous process that includes:

- Structured discussions to define key policy questions
- Ongoing expert panels and monthly scientific meetings
- Systematic literature reviews and evidence summaries
- Comparative analyses across vaccines and populations
- Data transparency, including a public protocol, allowing the results to be independently verified

"It is our duty as health care professionals to work across medicine, science and public **health to make sure the U.S. has a transparent, evidence-based process by which vaccine recommendations are made,**" said AMA Trustee Sandra Adamson Fryhofer, MD. "Together, we are committed to ensuring the American public has clear, evidence-based guidance that inspires confidence when making important vaccination decisions."

To begin, the Vaccine Integrity Project and the AMA will meet with medical societies to determine important policy questions that this process will seek to answer. For example, are there any newly published data to inform the need for additional doses of an RSV vaccine? From there, the Vaccine Integrity Project will begin to **assemble comprehensive scientific evidence briefs for influenza, COVID-19, and RSV by reviewing, extracting and synthesizing the newest published data on virology, epidemiology, vaccine effectiveness, and vaccine safety and will update medical societies about its findings.**

These briefs will be provided to participating medical societies—whose physician members are on the front lines of patient care—to develop and disseminate immunization guidance for their respective populations. As appropriate, societies will supplement the shared evidence base with population-specific data, such as guidance for pregnant women, children, older adults, immunocompromised individuals, and otherwise healthy adults.

Participants in the evidence review process will disclose relevant conflicts of interest, and the **Vaccine Integrity Project's review work will be independently funded through philanthropy.** The ultimate goal is to ensure that clinicians have access to credible, up-to-date evidence to inform patient care that is backed by the experts of our professional societies—even as the broader vaccine policy infrastructure in the United States remains under strain.

The need for sustained, evidence-based guidance is underscored by the measurable impact of vaccination. According to CDC estimates, influenza vaccination alone prevented nearly 10 million illnesses, about 120,000 hospitalizations, and nearly 8,000 deaths during the 2023–24 season. Yet almost 300 children died from influenza last flu season, the vast majority of whom were unvaccinated. COVID-19 vaccination continues to significantly reduce hospitalization risk among older adults and other high-risk populations, and RSV immunization continues to yield strong protective results for older adults and the youngest Americans...

American Osteopathic Association (AOA)

<https://osteopathic.org/news/>

(Accessed 14 Feb 2026)

Latest News

No new digest content identified.

American Public Health Association (APHA)

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName>Newest&sortMode=desc>
(Accessed 14 Feb 2026)

No new digest content identified.

Infectious Diseases Society of America (IDSA)

<https://www.idsociety.org/>
(Accessed 14 Feb 2026)
News releases and statements
No new digest content identified.

National Foundation for Infectious Diseases (NFID)

<https://www.nfid.org/news-updates/>
(Accessed 14 Feb 2026)
News and Updates
February 12, 2026

5 Reasons Why Vaccines Are Good for Your Heart

For people with heart disease, getting vaccinated is as important to staying healthy as diet and exercise

National Medical Association (NMA)

<https://nmanet.org/blog/>
(Accessed 14 Feb 2026)
Latest News
No new digest content identified.

Pediatric Infectious Diseases Society (PIDS)

<https://pids.org/news-announcements/>
(Accessed 14 Feb 2026)
News & Announcements
No new digest content identified.

Society for Healthcare Epidemiology of America (SHEA)

<https://shea-online.org/news/>
(Accessed 14 Feb 2026)
No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

<https://www.smfm.org/>
(Accessed 14 Feb 2026)
News
No new digest content identified.

:::::::
:::::::

Civil Society – Individuals, Organizations, Institutions *[Selected]*

:::::::

Kaiser Family Foundation/KFF [14 Feb 2026]

https://www.kff.org/search/?post_type=press-release

New KFF Poll Finds Trust in CDC Remains at Low Point Amid Falling Trust Among Democrats – These Findings and Others Included in New Polling Dashboard – The Monitor

Feb 12, 2026 *Feature*

KFF's latest Health Information and Trust Tracking Poll shows trust in the CDC for vaccine information is at its lowest point since the pandemic began. Findings are available on KFF's new polling dashboard. New evidence also finds no link between prenatal acetaminophen use and autism, though confusion may persist as officials question the drug's safety.

Shifting U.S. Vaccine Policy: Explaining Federal Actions and Exploring Public Opinion

Event Date: Feb 19, 2026

KFF experts share insights on what the shifting policy for childhood and adult vaccination schedules means for state governments, the U.S. public health system, and Americans.

KFF Dashboard: Progress Toward Global Malaria Targets in PMI Countries

Feb 11, 2026 *Interactive*

This dashboard monitors the status of the U.S. President's Malaria Initiative's (PMI) partner countries' progress toward global malaria targets.

HHS Public Health Policy Actions Under the Trump Administration 2025-2026

Feb 10, 2026 *Tracker*

A comprehensive timeline of public health policy actions by the Department of Health and Human Services (HHS) under the Trump administration from 2025-2026, with key dates, descriptions, and impacts.

Reliance on Sources Other Than CDC/ACIP for State Childhood Vaccine Recommendations

Feb 10, 2026 *State Health Facts Indicator*

KFF Tracker: America First MOU Bilateral Global Health Agreements

Feb 9, 2026 *Tracker*

This tracker provides up-to-date information on countries with signed bilateral MOU global health agreements with the U.S.

:::::::

Vaccine Integrity Project – CIDRAP [to 14 Feb 2026]

<https://www.cidrap.umn.edu/vaccine-integrity-project>

Announcements

Viewpoint -

Threats to Gavi mean placing ideology over saving lives

Feb. 9, 2026

:::::::

Paul Offit, MD – *Beyond the Noise*

Substack: <https://pauloffit.substack.com/>
[Selected]

RFK Jr's War on the World's Children

RFK Jr. has just withdrawn any future U.S. support from a program that has saved more than 20 million lives in resource-poor countries

Feb 10, 2026

:::::::

Peter Hotez

No new digest content identified.

:::::::

Art Caplan. Jonathan D. Moreno

Guest post: The CDC hepatitis B study is unethical and must never be published

Retraction Watch, February 10, 2026

...An unsolicited \$1.6 million grant to the Bandim Health Project at the University of Southern Denmark (SDU) would randomly assign more than 14,000 newborns into two groups, those who would receive the vaccine at birth and those who would act as a control group with delayed vaccination. The purpose of the controversial study was to assess the “broader health effects” of the vaccine for the control group.

But we already know the most critical health effect beyond the 48-months of the study: Withholding vaccination will predictably result in an increased incidence of liver disease later in life, including liver failure, cirrhosis and cancer. Therefore, the true scale of the tragedy brought on by this study would never be fully be known.

Already patently unethical, the study design would also exploit one of the world’s poorest countries...

:::::

:::::

Contents [click to move among sections]

- :: Milestones, Perspectives**
- :: WHO**
- :: Organization Announcements**
- :: Journal Watch**
- :: Pre-Print Servers**

:::::

:::::

Organization Announcements

Paul G. Allen Frontiers Group [14 Feb 2026]

<https://alleninstitute.org/news-press/>

News

News

Partnering with Anthropic to supercharge research and help cure disease

Feb 10, 2026

From months to hours, autonomous AI agents will accelerate research in the quest for cures.

Gates Foundation [14 Feb 2026]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

Statement by the Gates Foundation

The Gates Foundation is aware of emails recently released by the U.S. Department of Justice that include communication between Jeffrey Epstein and Gates Foundation staff. We will continue to review materials released in connection with this matter.

On the basis of Epstein's claims that he could mobilize significant philanthropic resources for global health and development, a small number of foundation employees interacted with Epstein to try to secure this potential funding. Ultimately, the foundation did not pursue any collaboration with Epstein and no fund was ever created. At no time were financial payments made by the foundation to Epstein, nor was he employed by the foundation at any time.

The harm Epstein inflicted on women and girls was horrific, and no one should ever have to experience what they did. The safety and wellbeing of women and girls is core to the foundation's mission of helping every person live a healthy and productive life, which we remain fully committed to. The foundation regrets having any employees interact with Epstein in any way.

CARB-X [14 Feb 2026]

<https://carb-x.org/>

News

No new digest content identified.

Chan Zuckerberg Initiative [14 Feb 2026]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [14 Feb 2026]

<http://cepi.net/>

CEPI News, Blog

CEPI Investment Case

Health protection for a vulnerable world**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 14

Feb 2026]

<https://cioms.ch/>

News; Publications; Events

Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION DRAFT REPORT

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences. Deadline to submit your comments is 13 March 2026.

DARPA – Defense Advanced Research Projects Agency [U.S.] [14 Feb 2026]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases Initiative [14 Feb 2026]

<https://dndi.org/press/press-releases/>

Press Releases

EVI supports first-in-human clinical trial of novel Nipah virus vaccine

In recent weeks, health authorities in India's state of West Bengal have confirmed cases of Nipah virus infection amid ongoing

10 Feb 2026

Duke Global Health Innovation Center [14 Feb 2026]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [14 Feb 2026]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [14 Feb 2026]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [14 Feb 2026]

<http://www.euvaccine.eu/>

News

06 Feb 2026

EVI supports first-in-human clinical trial of novel Nipah virus vaccine

In recent weeks, health authorities in India's state of West Bengal have confirmed cases of Nipah virus infection amid ongoing

Fondation Merieux [14 Feb 2026]

<http://www.fondation-merieux.org/>

Actualités

No new digest content identified.

Gates Medical Research Institute [14 Feb 2026]

<https://www.gatesmri.org/news>

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications

No new digest content identified.

Gavi [to 14 Feb 2026]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GE2P2 Global Foundation [14 Feb 2026]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements/Digests

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 06 Feb 2026](#)

:: [Genomics, Gene Editing, Convergent Biosciences: Governance, Ethics, Policy, Practice – A Monthly Review – Nov 2025](#)

GHIT Fund [14 Feb 2026]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 14 Feb 2026]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [14 Feb 2026]

<https://www.glopid-r.org/>

News & Events

[**GloPID-R Expands Its Activities to Strengthen Global Outbreak Preparedness**](#)

February 9, 2026

Building on the outcomes, decisions, and momentum generated during [GloPID-R's General Assembly](#), held on 27 – 28 October, 2025 in Paris, France, the GloPID-R network has expanded the scope of its activities to further strengthen coordination among funders, support strategic alignment, and contribute to accelerating effective global outbreak response.

Hilleman Laboratories [14 Feb 2026]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [14 Feb 2026]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [14 Feb 2026]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [14 Feb 2026]

<https://www.iavi.org/>

Press Releases, Features

No new digest content identified.

INSERM [14 Feb 2026]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 14 Feb 2026]

<https://www.ich.org/>

News/Pubs/Press Releases [Selected]

13 February 2026

Mock Example Developed to Illustrate Quality Modules of ICH M4Q(R2) Common Technical Document

The ICH M4Q(R2) Expert Working Group has developed a mock example to illustrate the potential structure and presentation of information in the revised Modules 2.3 and 3 of the Common Technical Document – Quality.

9 February 2026

Harmonised ICH M15 Guideline, General Principles for Model-informed Drug Development, Adopted

The ICH M15 Guideline, General Principles for Model-informed Drug Development, has been adopted and will now enter the implementation phase.

Ongoing Public Consultations ^

- > [Q3E EWG Guideline for Extractables and Leachables](#)
- > [E22 EWG General Considerations for Patient Preference Studies](#)
- > [M4Q\(R2\) EWG Revision of M4Q\(R1\)](#)

<https://www.ich.org/page/public-consultations>

ICRC [to 14 Feb 2026]

<https://www.icrc.org/en/news>

Latest press releases and statements

[South Sudan: Civilians pay a high price, as conflict intensifies](#)

News release 11-02-2026

[Working Together to Respect Human Rights and Humanitarian Law](#)

Statement 10-02-2026

IFFIm [14 Feb 2026]

<http://www.iffim.org/>

Press Releases/Announcements

IFRC [to 14 Feb 2026]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [14 Feb 2026]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [14 Feb 2026]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 14 Feb 2026]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

[Women remain underrepresented in scientific organizations, new evidence shows](#)

On 11 February 2026, marking the International Day of Women and Girls in Science, the International Science Council, the InterAcademy Partnership and the Standing Committee for Gender Equality in Science are launching a new global report examining gender equality in scientific

organizations. The report "Towards gender equality in scientific organizations: assessment and recommendations" finds that representation within these bodies continues to lag behind the composition of the wider scientific community, underscoring the need for sustained institutional action.

February 11, 2026

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News, Resources

No new digest content identified.

IVAC [14 Feb 2026]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [14 Feb 2026]

<http://www.ivi.int/>

IVI News & Announcements

Tackling AMR through vaccination in the Philippines and beyond

12 February 2026,

Johns Hopkins Center for Health Security [14 Feb 2026]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 14 Feb 2026]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

Latest News and Highlights

No new digest content identified.

MSF/Médecins Sans Frontières [to 14 Feb 2026]

<http://www.msf.org/>

Latest [Selected Announcements]

Ethiopia

MSF establishes a new project in Southwest Ethiopia Region

Project Update 12 Feb 2026

Conflict in Sudan

MSF launches an emergency response in El Obeid, southern Sudan

Project Update 11 Feb 2026

National Academy of Medicine - USA [to 14 Feb 2026]

<https://nam.edu/programs/>

News, Stories, Insights

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 14 Feb 2026]
<https://www.nationalacademies.org/newsroom>

News

[National Academy of Engineering Elects New Members](#)

News Release

The National Academy of Engineering today announced the election of its Class of 2026. With 130 new members and 28 international members, the total number of U.S. members is now 2,534 and the number of international members is 356. Election to the Academy is among the highest professional distinctions accorded to an engineer.

Feb 10, 2026

PATH [14 Feb 2026]

<https://www.path.org/media-center/>

Newsroom [Selected]

[PATH Kenya welcomes two new board members](#)

February 13, 2026 by Sintha Chiumia

PATH Kenya has announced the appointment of Dr. Njeri Gitau and Dr. William Mwiti Muriira to its Board of Directors, further strengthening its leadership in driving health innovation and equity.

Sabin Vaccine Institute [14 Feb 2026]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [14 Feb 2026]

<http://www.unaids.org/en>

News, Stories, Updates

Feature Story

[Strengthening partnerships to sustain the HIV response in Eastern Europe and Central Asia](#)

12 February 2026

UNICEF [to 14 Feb 2026]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Press release 11 February 2026

[Measles cases dropped in Europe and Central Asia in 2025 compared to the previous year, but the risk of outbreaks remains – UNICEF and WHO](#)

Unitaid [14 Feb 2026]

<https://unitaid.org/>

News releases

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [14 Feb 2026]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccine Confidence Project [14 Feb 2026]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [14 Feb 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter January 2026

Wellcome Trust [14 Feb 2026]

<https://wellcome.org/>

News, Opinion, Reports

Website not responding at inquiry.

The Wistar Institute [to 14 Feb 2026]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest announcements identified.

World Bank [to 14 Feb 2026]

<http://www.worldbank.org/en/news/all>

News [Selected]

Current Deficits in Nutrition, Learning, and On-the-Job Skills Are Costing Children Born Today Half of Their Future Earnings

ABUJA, February 12, 2026— Current deficits in health, education, and skill development at work are costing low- and middle-income countries 51% of their future labor earnings, according to a new World...

Date: February 12, 2026 Type: *Press Release*

WFPHA: World Federation of Public Health Associations [14 Feb 2026]

<https://www.wfpha.org/>

Blog, Events

No new digest announcements identified.

World Medical Association [WMA] [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest announcements identified.

World Organisation for Animal Health [OIE] [14 Feb 2026]

<https://www.oie.int/>

Press Releases, Statements

No new digest announcements identified.

::::::

::::::

ARM [Alliance for Regenerative Medicine] [14 Feb 2026]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest announcements identified.

BIO [14 Feb 2026]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [14 Feb 2026]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [14 Feb 2026]

<https://internationalbiotech.org/>

News

No new digest announcements identified.

IFPMA [14 Feb 2026]

<https://ifpma.org/>

News & Resources

Statement 9 Feb 2026

Statement at the fifth meeting of the open-ended Intergovernmental Working Group (IGWG 5) on the WHO Pandemic Agreement

On 9 February 2026 in Geneva, IFPMA delivered a statement at the fifth meeting of the open-ended Intergovernmental Working Group (IGWG 5) on the WHO Pandemic Agreement.

International Alliance of Patients' Organizations – IAPO [14 Feb 2026]

<https://www.iapo.org.uk/news>

Press and media [Selected]

IAPO participates in the 158th WHO Executive Board 2026

Tuesday, 10 February 2026

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [14 Feb 2026]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

::::::

::::::

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - *No new digest announcements identified.*

Bavarian Nordic

Latest News - *No new digest announcements identified.*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified.*

Biological E

News - *No new digest announcements identified.*

BioNTech

Press Releases - *No new digest announcements identified.*

Boehringer

Press Releases - *No new digest announcements identified.*

CanSinoBIO

News - *Website not responding at inquiry.*

CIGB

Latest News - *No new digest announcements identified.*

CinnaGen

Recent News - *No new digest announcements identified.*

Clover Biopharmaceuticals – China

News - *No new digest announcements identified.*

CSL Sequirus

News Releases - *No new digest announcements identified.*

Curevac

News - *Website now directs to BioNTech site*

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]
<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

GSK's RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older

:: If approved, Arexvy will be the first vaccine available in China for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older
:: RSV affects over six million people aged 60 and older in China each year¹

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Moderna

News and Blog Posts

Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

:: Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has requested a Type A meeting to understand the path forward

:: mRNA-1010 has been submitted and accepted for review in the EU, Canada and Australia

:: Company does not expect any impact on its 2026 financial guidance

February 10, 2026

..."This decision by CBER, which did not identify any safety or efficacy concerns with our product, does not further our shared goal of enhancing America's leadership in developing innovative medicines," said Stéphane Bancel, Chief Executive Officer of Moderna. "It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting. We look forward to engaging with CBER to understand the path forward as quickly as possible so that America's seniors, and those with underlying conditions, continue to have access to American-made innovations."

Moderna has requested a Type A meeting with CBER to understand the basis for the RTF letter. In the interest of transparency, the Company has posted the full letter on its website, linked here...

Nanogen

News - - Website not responding at inquiry.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Samsung Biologics

Latest News - No new digest announcements identified.

Sanofi Pasteur

Press Releases

February 12, 2026

[Press Release: Belén Garijo to become Chief Executive Officer of Sanofi](#)

Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026 at the end of business. The Board thanks him for his valuable contributions to the transformation and development of the Group over the last six years.

Following the proposal of the Appointments Committee, the Board of Directors appointed Belén Garijo as Chief Executive Officer. She will take up her duties at the end of the Group's Annual General Meeting on April 29, 2026. The Board will also propose to the shareholder vote the candidacy of Belén Garijo as a director of the Group(*).

Olivier Charmeil, Executive Vice President, General Medicines, and member of the Executive Committee since 2011, will assume the role of Interim Chief Executive Officer during this transition...

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

February 13, 2026

[Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom](#)**WestVac Biopharma**

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

::::::

::::::

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

::::::

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/aging-bad-you>

Aging Is Bad for You?

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

American Journal of Human Genetics

Feb 05, 2026 Volume 113 Issue 2 p235-400

<https://www.cell.com/ajhg/current>

This month in The Journal

Paul W. Hook, Alyson B. Barnes

The current biotechnology industry is characterized by intense competition. Although this competition can drive innovation and increased investment, too much competition can prevent collaboration and potentially foster a culture in which data and methods are stockpiled and guarded. The United States Federal Trade Commission (FTC) advances government policies that promote free and open competition and challenges anticompetitive business practices. In this issue, Rashid et al. provide an overview of recent policy changes at the FTC surrounding competition and innovation in human genetics and genomics, using the Illumina and Grail merger in 2021 as a case study.

[Reviewed earlier]

American Journal of Infection Control

February 2026 Volume 54 Issue 2 p107-240

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

February 2026 Volume 70 Issue 2

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

January 2026 116(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 114 (2026): Issue 2 (Feb 2026)

<https://www.ajtmh.org/view/journals/tpmd/114/2/tpmd.114.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2026 Volume 179, Issue 1

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 351 February 2026

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/351/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 14 Feb 2026)
[No new digest content identified]

BMC Health Services Research
<http://www.biomedcentral.com/bmchealthservres/content>
(Accessed 14 Feb 2026)
[No new digest content identified]

BMC Infectious Diseases
<http://www.biomedcentral.com/bmcinfectdis/content>
(Accessed 14 Feb 2026)
[Mpox comprehensive assessment for responsive immunisation in emergency outbreaks \(MpoxCARE\): study protocol](#)
Karishma Gokani, Herve Semukunzi
The MpoxCARE Study Group
Study Protocol Open access 13 February 2026

[Trends in bacterial meningitis in Guinea in the post-MenAfriVac era: a retrospective cross-sectional study \(2021–2024\)](#)
Mamadou Bobo Diallo, Iman Frédéric Youa, Kaba Kourouma
Research Open access 10 February 2026

BMC Medical Ethics
<http://www.biomedcentral.com/bmcmedethics/content>
(Accessed 14 Feb 2026)
[No new digest content identified]

BMC Medicine
<http://www.biomedcentral.com/bmcmed/content>
(Accessed 14 Feb 2026)
[Clinical impact and cost-effectiveness of vaccinating infants and adolescents against invasive meningococcal B disease in the Netherlands](#)
Thomas Otten, Mirjam Knol, Anneke Steens
Research Open access 10 February 2026

BMC Pregnancy and Childbirth
<http://www.biomedcentral.com/bmcpregnancychildbirth/content>
(Accessed 14 Feb 2026)
[No new digest content identified]

BMC Public Health
<http://bmcpublichealth.biomedcentral.com/articles>
(Accessed 14 Feb 2026)
Articles
[COVID-19 testing and vaccination uptake among Spanish-speaking Latine persons: impact of a novel social network intervention](#)

Sandy K. Aguilar-Palma, Thomas P. McCoy, Scott D. Rhodes
Research Open access 11 February 2026

Leveling up immunization: a systematic review of gamification interventions to improve Human Papillomavirus (HPV) vaccine uptake

Shafaq Taseen, Ramsha Ayub, Mohammad Tahir Yousafzai
Systematic Review Open access 11 February 2026

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>
(Accessed 14 Feb 2026)
[No new digest content identified]

BMJ Evidence-Based Medicine

December 2025 - Volume 30 - 6
<https://ebm.bmj.com/content/30/6>
[Reviewed earlier]

BMJ Global Health

January 2026 - Volume 11 - 1
<https://gh.bmj.com/content/11/1>
[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - December 2025
<https://thebulletin.org/magazine/2025-12/#post-heading>
[Reviewed earlier]

Bulletin of the World Health Organization

Volume 104, Number 2, February 2026, 61-136
[Reviewed earlier]

Cell

Jan 22, 2026 Volume 189 Issue 2 p343-696
<https://www.cell.com/cell/current>
[Reviewed earlier]

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4
<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>
[Reviewed earlier]

Child Care, Health and Development

Volume 52, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 119, Issue 2 Pages: 281-563 February 2026

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

February 2026 Volume 48 Issue 2 p135-212

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

Clinical Trials

Volume 22 Issue 6, December 2025

<https://journals.sagepub.com/toc/ctja/22/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 14 Feb 2026]

[No new digest content identified]

Contemporary Clinical Trials

Volume 161 February 2026

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/161/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 6 / December 2025

<https://www.liebertpub.com/toc/crispr/8/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2026 - Volume 39 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[New issue; No digest content identified]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 14 Feb 2026]

[No new digest content identified]

Cytotherapy

March 2026 Volume 28 Issue 3

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 4 Pages: 253-323 December 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 35, Issue 5, 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 44, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 50, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 124 February 2026

<https://www.sciencedirect.com/journal/ebiomedicine/vol/124/suppl/C>

[New issue; No digest content identified]

EMBO Reports

Volume 27, Issue 3 February 2026

<https://link.springer.com/journal/44319/volumes-and-issues/27-3>

[New issue; No digest content identified]

Emerging Infectious Diseases

Volume 32, Number 1—January 2026

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 53 December 2025

<https://www.sciencedirect.com/journal/epidemics/vol/53/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 154 - 2026

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 48, Issue 1 Pages: 1-48 January–February 2026

<https://onlinelibrary.wiley.com/toc/25782363/current>

Research and pregnant women • Considerations for informed consent

[Reviewed earlier]

Ethics & International Affairs

Volume 39 - Issue 3 - Fall 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 6, December 2025

<https://academic.oup.com/eurpub/issue/35/6>

[Reviewed earlier]

Expert Review of Vaccines

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

January/February 2026 Volume 105, Number 1

<https://www.foreignaffairs.com/issues/2026/105/1>

[Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 14 Feb 2026]

Opinion - Published on 13 Feb 2026

[Imagining an ethics for synthetic biology](#)

Varsha Aravind Paleri, Kristien Hens

Editorial - Published on 13 Feb 2026

[Editorial: Advancements in AI for the analysis and interpretation of large-scale data by omics techniques](#)

Angelo Facchiano, Deborah Giordano, Dominik Heider

Editorial - Accepted on 10 Feb 2026

[Editorial: Integrating Genetics and Proteomics for Drug Discovery](#)

Karunakaran Kalesh, Liang Xue

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 14 Feb 2026]

[No new digest content identified]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 14 Feb 2026]

[No new digest content identified]

Gene Therapy – Nature

Volume 32 Issue 6, December 2025

<https://www.nature.com/gt/volumes/32/issues/6>

[Reviewed earlier]

Genetics in Medicines

Volume 28, Issue 2 February 2026

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/2>

[New issue; No digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 14 Feb 2026]

[No new digest content identified]

Global Health Action

Volume 19, Issue 1 (2026)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

December 2025 | Volume 13 | Number 2

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 14 Feb 2026]

[No new digest content identified]

Global Public Health

Volume 21, Issue 1 (2026)

<http://www.tandfonline.com/toc/rgph20/current>

Article

[Exploring drivers of childhood vaccine hesitancy among caregivers in Brazil and South Africa: A qualitative study](#)

Camila C. Matos, Elizabeth O. Oduwole, Edina Amponsah-Dacosta, Imen Ayouni, Charles S. Wiysonge & Marcia Thereza Couto

Article: 2607248

Published online: 21 Jan 2026

Article

['Outbreak distress': Characterising moral distress among international healthcare workers responding to mpox](#)

Rosalie Hayes, Anthony K. J. Smith, Sara Paparini, Vanessa Apea, Martin Holt & Chloe Orkin

Article: 2607848

Published online: 02 Feb 2026

Comment

Resurgence of measles in the United States: Examining the outbreak, vaccine hesitancy, and future directions

Majani Edward

Article: 2624148

Published online: 30 Jan 2026

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 14 Feb 2026]

[No new digest content identified]

Health and Human Rights

Volume 27, Issue 2, December 2025

<https://www.hhrjournal.org/volume-27-issue-2-december-2025/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 21 - Issue 1 - January 2026

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 10, November 2025

<https://academic.oup.com/heapol/issue/40/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 14 Feb 2026]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 23-24 / December 2025

https://www.liebertpub.com/toc/hum/36/2_3-24

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

[Accessed 14 Feb 2026]

[No new digest content identified]

Immunity

Jan 13, 2026 Volume 59 Issue 1 p1-228

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 14 Feb 2026]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 14 Feb 2026]

[No new digest content identified]

International Health

Volume 17, Issue 6, November 2025

<https://academic.oup.com/inthealth/issue/17/6>

[Reviewed earlier]

International Human Rights Law Review

Volume 14 (2025): Issue 1 (Jun 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 12 (2025): December 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/131>

[Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 5, October 2025

<https://academic.oup.com/ije/issue/54/5>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18, Issue 5 4 November 2025

<https://www.emerald.com/ijhrh/issue/18/5>

[Reviewed earlier]

JAMA

February 10, 2026, Vol 335, No. 6, Pages 473-560

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

Trends in County-Level Childhood Vaccination Exemptions in the US

Mustafa Fattah, MS, MPhil; Lauren A. Stoffel; Kate M. Bubar, PhD; et al.

JAMA. 2026;335(6):546-549. doi:10.1001/jama.2025.24407

This study examines US county-level trends in nonmedical and medical exemptions to childhood vaccination requirements.

Medical News

Hundreds of Medical Groups Challenge Childhood Immunization Schedule Changes—Here's What to Know

Rita Rubin, MA

JAMA. 2026;335(6):475-477. doi:10.1001/jama.2026.0095

This Medical News article discusses changes to the US government's childhood and adolescent immunization schedule and what they mean for clinicians and families.

JAMA Health Forum

January 2026, Vol 7, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

January 2026, Vol 180, No. 1, Pages 3-120

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

January 2026 - Volume 24 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

February 2026 Volume 78 Issue 2 p203-370

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Bioethical Inquiry

Volume 22, Issue 3 September 2025

<https://link.springer.com/journal/11673/volumes-and-issues/22-3>

[Reviewed earlier]

Journal of Community Health

Volume 50, Issue 6 December 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

Journal of Development Economics

Volume 178 January 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/178/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 5, December 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

February 2026 - Volume 80 - 2

<https://jech.bmjjournals.org/content/80/2>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 4 December 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 21, Issue 2 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 4, November 2025

<https://muse.jhu.edu/issue/55986>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 5 October 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 24, Issue 1 (2026)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 38, Issue 1 Pages: 1-191 January 2026

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Law, Medicine & Ethics

Volume 53 - Issue 3 - Fall 2025

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

Public Health, Markets, and Law

[Reviewed earlier]

Journal of Medical Ethics

February 2026 - Volume 52 - 2

<http://jme.bmjjournals.org/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 288 January 2026

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/288/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

November/December 2025 - Volume 31 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 4 December 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-4>

[Reviewed earlier]

Journal of the Royal Society – Interface

Volume 23, Issue 235 1 February 2026

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 33, Issue 1, January 2026

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

The Lancet

Feb 14, 2026 Volume 407 Number 10529 p649-732

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

The Lancet Child & Adolescent Health

Feb 2026 Volume 10 Number 2 p71-146, e4-e9

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Dec 2025 Volume 7 Number 12

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Feb 2026 Volume 14 Number 2 e173-e310

<https://www.thelancet.com/journals/langlo/issue/current>

Articles

[7-year trend of timely hepatitis B birth dose vaccination coverage in The Gambia: a retrospective, population-based analysis](#)

Gibril Ndow, et al.

According to WHO and UNICEF, Africa has the lowest coverage (18%) of timely (within the first 24 h) hepatitis B birth dose (HepB-BD) vaccination worldwide. To eliminate hepatitis B by 2030, 90% vaccination coverage is required. Experiences from The Gambia, the first African country to adopt HepB-BD vaccination in 1990, could guide HepB-BD implementation and scale-up in Africa. We aimed to assess the trend of, and barriers to, timely HepB-BD vaccination coverage over a 7-year period in The Gambia... 30 years after the adoption of HepB-BD in The Gambia, the rate of vaccination coverage remains low and was significantly affected by the COVID-19 pandemic, highlighting the challenges for its implementation.

Lancet Infectious Diseases

Feb 2026 Volume 26 Number 2 p111-212, e77-e131
<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Feb 2026 Volume 11 Number 2 e69-e136
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Feb 2026 Volume 14 Number 2 p99-186, e9-e18
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 10 October 2025
<https://link.springer.com/journal/10995/volumes-and-issues/29-10>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 46 Issue 1, January 2026
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 103, Issue S1 Pages: 1-462 November 2025
<https://onlinelibrary.wiley.com/toc/14680009/current>
Special Issue: Mental Health and Substance Use Challenges Facing the United States: What Can State Policy Makers Do
[New issue; No digest content identified]

Molecular Therapy

Feb 04, 2026 Volume 34 Issue 2 p645-1292
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 650 Issue 8101, 12 February 2026
<https://www.nature.com/nature/volumes/650/issues/8100>
Editorial 11 Feb 2026
African countries must take control of health policy

Massive cuts to global health-care funding have had a huge impact on the continent, but a more resilient system can be built from within.

World View 10 Feb 2026

How to rescue the aid industry: focus on conflict prevention, not just relief

In an era of escalating conflict, a development-only approach to aid will yield fleeting results.
Rabah Arezki

Nature Biotechnology

Volume 44 Issue 1, January 2026

<https://www.nature.com/nbt/volumes/44/issues/1>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 14 Feb 2026)

[Reviewed earlier]

Nature Genetics

Volume 58 Issue 1, January 2026

<https://www.nature.com/ng/volumes/58/issues/1>

[Reviewed earlier]

Nature Human Behaviour

Volume 10 Issue 1, January 2026

<https://www.nature.com/nathumbehav/volumes/10/issues/1>

[Reviewed earlier]

Nature Medicine

Volume 32 Issue 1, January 2026

<https://www.nature.com/nm/volumes/32/issues/1>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 25 Issue 1, January 2026

<https://www.nature.com/nrd/volumes/25/issues/1>

[Reviewed earlier]

Nature Reviews Genetics

Volume 27 Issue 1, January 2026

<https://www.nature.com/nrg/volumes/27/issues/1>

[Reviewed earlier]

Nature Reviews Immunology

Volume 26 Issue 2, February 2026

<https://www.nature.com/nri/volumes/26/issues/2>

[Reviewed earlier]

New England Journal of Medicine Volume

Volume 394 No. 7 February 12, 2026

<https://www.nejm.org/toc/nejm/medical-journal>

Sounding Board

From the National Academy of Medicine: Improving Regulations for Human Subjects

Research

L. Coleman and K. Wullert

NEJM Evidence

Volume 4 No. 12 December 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 14 Feb 2026]

[No new digest content identified]

Pediatrics

Volume 157, Issue 1 January 2026

<https://publications.aap.org/pediatrics/issue/157/1>

[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 12 December 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-12>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 14 Feb 2026)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 14 Feb 2026)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 14 Feb 2026)

[Uptake of malaria vaccine \(RTS,S/AS01\) among children aged 6–24 months: A cross-sectional survey conducted in the Western region of Cameroon, 1 year following the vaccine introduction](#)

Jerome Ateudjieu, Merveille Claire Nana Djapou, Benjamin Kevin Bekoa Onana, Abdias Aron Tatsabong Tiomeni, Gretta Ludivine Okoumokath Mpande, Donald Kapso Nanguep, Collins Buh Nkum, Dora Winny Ateudjieu Kenfack, Anne Cecile Bissek

Research Article | published 13 Feb 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0005304>

[Timeliness of vaccine administration among children in urban informal settlements in Nairobi, Kenya](#)

Maurine Ng’oda, Jonathan Izudi, Collins Omenda, Anne Njeri, Nelson Mbaya, Abdhalah Ziraba

Research Article | published 11 Feb 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0005462>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 14 Feb 2026)

[Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study](#)

Natalie Carvalho, Emma Watts, Victoria L. Oliver, Andrew Clark, Murat Hakan Ozturk, Siale Akuola, Clare Whelan, Take Naseri, Kylie Jenkins, Inez Mikkelsen-Lopez, Ki Fung Kelvin Lam, Rommel Rabanal, Ross McLeod, Mark Jit, Fiona M. Russell

Research Article | published 12 Feb 2026 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004604>

[Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study](#)

Hira Tanvir, Rebecca A. Clark, Tom Sumner, Katherine C. Horton, Tomos O. Prŷs-Jones, Roel Bakker, Kirankumar Rade, Vidya Mave, Mark Hatherill, Gavin Churchyard, Rein M. G. J. Houben, Richard G. White

Research Article | published 12 Feb 2026 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004595>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 14 Feb 2026)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 14 Feb 2026]

[Uptake of measles second dose vaccine among children aged 15–35 months at Mettu Woreda, Illu Aba Bor Zone, Ethiopia: A community-based cross-sectional study](#)

Alemayehu Workiye Haile, Ebissa Bayana Kebede, Vinod Bagilkar, Teklu Wosenyeleh Mamo, Maycas Gembe

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 14 Feb 2026]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

February 10, 2026 vol. 123 no. 6

<https://www.pnas.org/toc/pnas/123/6>

Perspective February 3, 2026

[A framework for assessing the trustworthiness of scientific research findings](#)

Vigorous debate has erupted over the trustworthiness of scientific research findings in a number of domains. The question "what makes research findings trustworthy?" elicits different answers depending on whether the emphasis is on research integrity and ...

Brian A. Nosek, David B. Allison, [...] Susan M. Wolf

PNAS Nexus

Volume 4, Issue 11, November 2025

<https://academic.oup.com/pnasnexus/issue/4/11>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 6 - December 2025

<https://www.cambridge.org/core/journalsprehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 203 February 2026

<https://www.sciencedirect.com/journal/preventive-medicine/vol/203/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

Volume 293, Issue 2063 January 2026

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 249 December 2025

<https://www.sciencedirect.com/journal/public-health/vol/249/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025
<http://phe.oxfordjournals.org/content/current>
[Reviewed earlier]

Public Health Genomics
2025, Vol. 28, No. 1
<https://karger.com/phg/issue/28/1>
[Reviewed earlier]

Public Health Reports
Volume 140 Issue 5-6, Sep-Oct/Nov-Dec 2025
<https://journals.sagepub.com/toc/phrg/140/5-6>
[Reviewed earlier]

Qualitative Health Research
Volume 36 Issue 1, January 2026
<https://journals.sagepub.com/toc/QHR/current>
[Reviewed earlier]

Research Ethics
Volume 22 Issue 1, January 2026
<http://journals.sagepub.com/toc/reab/current>
[Reviewed earlier]

Reproductive Health
<http://www.reproductive-health-journal.com/content>
[Accessed 14 Feb 2026]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
<https://www.paho.org/journal/en>
Latest Articles
13 Feb 2026
[**Early onset of seasonal influenza and emerging RSV activity: Implications for health systems**](#)
Special report | English |

Risk Analysis
Volume 46, Issue 1 January 2026
<https://onlinelibrary.wiley.com/toc/15396924/current>
[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 14 Feb 2026]

[No new digest content identified]

Royal Society Open Science

Volume 13, Issue 2 1 February 2026

[Reviewed earlier]

Science

Volume 391| Issue 6786| 12 Feb 2026

<https://www.science.org/toc/science/current>

Editorial

[Taking a sharp turn](#)

BY Theresa A. Maldonado

12 Feb 2026

This week, the American Association for the Advancement of Science (AAAS, the publisher of Science) convenes its annual meeting in Phoenix, Arizona. The meeting's theme, "Science at Scale," stands in stark contrast to the diminishing of science by the current US federal administration. Amid political attempts to weaken science, this gathering of people from academia, industry, government, business, medicine, law, ethics, and other sectors is an opportunity to look to the future...

Science and Engineering Ethics

Volume 31, Issue 6 December 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-6>

[Reviewed earlier]

Science Translational Medicine

Volume 18| Issue 835| 4 Feb 2026

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 14 Feb 2026]

[No new digest content identified]

Social Science & Medicine

Volume 386 December 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/386/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 14 Feb 2026]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 6 December 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 68 November–December 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/68/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 31, Issue 1 Pages: 1-111 January 2026

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 74 27 February 2026

<https://www.sciencedirect.com/journal/vaccine/vol/74/suppl/C>

Review article Open access

[A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults](#)

Helen Lister, Katherine Farquharson, Holly Seale, Louise E. Smith, ... G. James Rubin

Article 128195

Research article Abstract only

[Anti-vaccination attitudes and behavioral intentions towards three recommended vaccinations among Chinese older adults with chronic diseases: A multicenter cross-sectional study](#)

Mengyue Zhang, Siwen Huang, Chi Ruan, Yan Jiang, ... Sitong Luo

Article 128191

Research article Open access

[Mind the gap: A qualitative assessment of limitations in school-age immunisation programme delivery for Orthodox Jewish children in northeast London](#)

Ben Kasstan-Dabush, Tehseen Khan, Vanessa Saliba, Tracey Chantler

Article 128193

Research article Abstract only

[Effectiveness of information interventions in reducing HPV vaccine hesitancy: a randomized survey experiment in China](#)

Yunshu Lu, Wei Zhao, Sen Xu, Chengzhou Tang, ... Jie Chang

Article 128205

Research article Abstract only

[Prioritization of HPV vaccine preventable diseases among emerging adults – Implications for health education and communication](#)

Evan G. Coblenz, Caroline R. Packee, Samantha L. Ky, Avery G. Brubaker, ... Shandey D. Malcolm

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 14 Feb 2026]

[No new digest content identified]

Value in Health

February 2026 Volume 29 Issue 2 p175-346

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Medical Journal – Official Journal of The World Medical Association

Nr. 4, December 2025, vol. 71

<https://www.wma.net/publications/world-medical-journal/>

[Reviewed earlier]

World Development

Volume 200 April 2026

<https://www.sciencedirect.com/journal/world-development/vol/200/suppl/C>

[Reviewed earlier]

::::::

::::::

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

::::::

::::::

Pre-Print Servers

arXiv

<https://arxiv.org/>

[Accessed 14 Feb 2026]

[*Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

arXiv:2602.08061 (cross-list from cs.AI) [[pdf](#), [html](#), [other](#)]

[Securing Dual-Use Pathogen Data of Concern](#)

[Doni Bloomfield](#), [Allison Berke](#), [Moritz S. Hanke](#), [Aaron Maiwald](#), [James R. M. Black](#), [Toby Webster](#), [Tina Hernandez-Boussard](#), [Oliver M. Crook](#), [Jassi Pannu](#)

Comments: 39th Conference on Neural Information Processing Systems (NeurIPS 2025) Workshop: Biosecurity Safeguards for Generative AI

Training data is an essential input into creating competent artificial intelligence (AI) models. AI models for biology are trained on large volumes of data, including data related to biological sequences, structures, images, and functions. The type of data used to train a model is intimately tied to the capabilities it ultimately possesses--including those of biosecurity concern. For this reason, an international group of more than 100 researchers at the recent 50th anniversary Asilomar Conference endorsed data controls to prevent the use of AI for harmful applications such as bioweapons development. To help design such controls, we introduce a five-tier Biosecurity Data Level (BDL) framework for categorizing pathogen data. Each level contains specific data types, based on their expected ability to contribute to capabilities of concern when used to train AI models. For each BDL tier, we propose technical restrictions appropriate to its level of risk. Finally, we outline a novel governance framework for newly created dual-use pathogen data. In a world with widely accessible computational and coding resources, data controls may be among the most high-leverage interventions available to reduce the proliferation of concerning biological AI capabilities.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 14 Feb 2026]

[*Filter: All articles*]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 14 Feb 2026]

[*Filter: All articles*]

Novel Representations of Vaccine Protection Against Progression to Severe Disease Over Time

Natalie Dean, Veronika Zarnitsyna

medRxiv 2026.02.12.26346197; doi: <https://doi.org/10.64898/2026.02.12.26346197>

Clinical presentation of severe malaria in children who received the RTS,S/AS01E malaria vaccine, seasonal malaria chemoprevention or the combination of both interventions in Burkina Faso and Mali.

Djibrilla Issiaka, Issaka Zongo, Youssoufa Sidibe, Yves Daniel Compaore, Rakiswende Serge Yerbanga, Mahamadou Kaya, Charles Zoungrana, Romaric Oscar Zerbo, Oumar M Dicko, Youssouf Kone, Amadou Tapiily, Seydou Traore, Koualy Sanogo, Modibo Diarra, Amadou Barry, Almahanoudou Mahamar, Alassane Haro, Ismaila Thera, M Sanni Ali, Paul Snell, Jane Grant, Irene Kuepfer, Cynthia K Lee, Christian F Ockenhouse, Opokuwa Ofori-Anyinam, Paul Milligan, Issaka Sagara, Halidou Tinto, Jean Bosco Ouedraogo, Daniel Chandramohan, Brian Greenwood, Alassane Dicko
medRxiv 2026.02.11.26344823; doi: <https://doi.org/10.64898/2026.02.11.26344823>

Capacity building in the global polio eradication initiative: individual wins and institutional opportunities, a qualitative analysis

Koumudi Thanda, Anna Kalbarczyk, Oluwaseun Akinyemi, Humayra Binte Anwar, Wakgari Deressa, Eric Mafuta, Yodi Mahendradhata, Piyusha Majumdar, Ahmad Omid Rahimi, Olakunle Alonge
medRxiv 2026.02.10.26346031; doi: <https://doi.org/10.64898/2026.02.10.26346031>

The Global Polio Eradication Initiative (GPEI) is known to be one of the most successful disease eradication initiatives with massive reductions in polio transmission as well as its contributions to strengthening health systems and capacity building. Existing analyses provide limited insight into how capacity was developed, which forms of capacity were strengthened or neglected, and how these efforts were experienced by implementers. Understanding these factors can be helpful as GPEI

accelerates transition and integration into national health systems. This study examines GPEI's capacity-building efforts from the perspectives of GPEI workers across multiple roles, levels and countries...

CHANGES IN INCIDENCE AND SEROTYPE DISTRIBUTION OF PEDIATRIC INVASIVE PNEUMOCOCCAL DISEASE AFTER THE INTRODUCTION OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CATALONIA, SPAIN. A MULTICENTER SURVEILLANCE STUDY

C Muñoz-Almagro, M Cisneros, C Alcaraz, S Broner, F Moraga-Llop, A Rosell, A Diaz-Conradi, P Brotons, D Henares, G Gonzalez-Comino, B Viñado, F Gómez-Bertomeu, C Marco, S Gonzalez-Peris, J Llaberia, C Izquierdo, J Galvez, A Perez-Argüello, R Varo, J Iglesias, C Esteva, M Armas, M Blanco-Fuertes, N Torrellas, MO Perez, IT Valle, M Navarro, A Rivera, M Colomer, L Solaz, M Mico, JJ Garcia-Garcia, A Dominguez, MF de Sevilla, P Ciruela

medRxiv 2026.02.11.26346066; doi: <https://doi.org/10.64898/2026.02.11.26346066>

Three Dimensions of Compounding Neglect: How Biobanks, Clinical Trials, and Scientific Literature Systematically Exclude the Global South

Manuel Corpas, Maxim B. Freidin, Julio Valdivia-Silva, Simeon Baker, Segun Fatumo, Heinrich Guio
medRxiv 2026.02.10.26346004; doi: <https://doi.org/10.64898/2026.02.10.26346004> Revision

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 14 Feb 2026]

Open Letter Open Access

The Discovery Research Platform for Medical Humanities responds to the Wellcome Trust's report on Archives, manuscripts and material culture (AMCs) in life, health, and wellbeing research

[version 1; peer review: awaiting peer review]

Harriet Barratt, Fiona Johnstone, Coreen McGuire

Abstract

This open letter from Durham University's Discovery Research Platform for Medical Humanities responds to the Wellcome Trust's 2025 report on archives, manuscripts, and material culture (AMCs) in health research. We applaud the report's recognition of AMCs as foundational infrastructures for discovery research and its emphasis on pluralistic values, and we use this letter to expand upon three critical dimensions...

*

*

*

*

Think Tanks

Brookings [to 14 Feb 2026]

<http://www.brookings.edu/>

Research, Events

No new digest content identified.

Center for Global Development [14 Feb 2026]

<https://www.cgdev.org/>

All Research

CGD NOTE

[Rolling Out the Trump Administration's Global Health Agreements: What Can We Learn from Past Government-to-Government Assistance?](#)

Jocelyn Estes

February 13, 2026

Bilateral health agreements are a cornerstone of the Trump administration's second-term approach to foreign assistance. But the push to cut out intermediaries extends well beyond global health. G2G mechanisms could be deployed at a far greater scale, and on even longer time horizons, to deliver deve...

Chatham House [to 14 Feb 2026]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [14 Feb 2026]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 14 Feb 2026]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

IS Global [to 14 Feb 2026]

<https://www.isglobal.org/en/>

Institutional

[Towards Faster Diagnosis of Congenital Chagas in Latin America](#)

09.02.2026

McKinsey Global Institute [to 14 Feb 2026]

<https://www.mckinsey.com/mgi/overview>

Featured Research

No new digest content identified.

ODI [Overseas Development Institute] [to 14 Feb 2026]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 14 Feb 2026]

<https://www.pewresearch.org/>

Latest Publications

Report Feb 12, 2026

Religious Diversity Around the World

Singapore is the most religiously diverse country, and Yemen the least, as of 2020. The U.S. ranks first among nations with large populations.

Rand [to 14 Feb 2026]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Expert Insights Feb 10, 2026

Measuring Biological Capabilities and Risks of AI Agents: Generating and Interpreting Evidence from Agentic Evaluations

This perspective examines biological agentic evaluations as a tool for assessing risks from increasingly autonomous AI systems and offers practical guidance on how evaluation design shapes conclusions about biological capability and risk.

Urban Institute [to 14 Feb 2026]

<https://www.urban.org/research>

New Research Publications - Selected

No new digest content identified.

World Economic Forum [to 14 Feb 2026]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

:::::

:::::

Public Consultations/Call for Inputs/Call for Papers

Request for Information on Draft NIH Controlled-Access Data Policy and Proposed Revisions to NIH Genomic Data

NATIONAL INSTITUTES OF HEALTH (NIH) Notice Number: NOT-OD-26-023 **Response Date:**
March 18, 2026

Purpose

The National Institutes of Health (NIH) is requesting public input on its proposal to establish harmonized and transparent policy requirements for protecting human participant research data. Specifically, NIH proposes (1) establishing policy requirements for which data should be controlled-access under NIH data sharing policies, and (2) revising the NIH Genomic Data Sharing Policy to simplify and harmonize requirements.

Background

NIH serves as the steward of a wide range of research data and continuously works to optimize open sharing with appropriate protections throughout the entire data lifecycle. Given its numerous established data policies, NIH is proposing a holistic update to its data policy framework to strengthen data protections, clarify requirements, and reduce duplicative burden.

NIH is proposing a new NIH Controlled-Access Data Policy to support the research community in fulfilling NIH data sharing expectations. This proposed policy specifies human participant data types required to be managed via controlled-access and provides criteria for assessing the need for controls for other data types. It also provides a standard set of expectations across NIH Institutes, Centers and Offices to promote maximal responsible human participant data sharing through controlled access while simultaneously responding to emergent privacy and security risks, including those outlined in the following security directives...

Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION DRAFT REPORT

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences.

Medicines are public health tools. With regard to the quality and transparency of the assessment of their effectiveness and safety, they are increasingly subject to the expectations and requirements of patients, healthcare professionals and regulators. Those involved in the development and delivery of medicines must therefore take full account of the aforementioned paradigm shifts. Additionally, the arrival of novel therapeutic agents, such as gene therapy, biologics and mRNA vaccines, whose modes of action and interactions with living organisms have very little in common with those of the more traditional chemical medicines, has brought into question the classic elements of pharmacovigilance and pharmacoepidemiology, such as the dose–effect relationship, drug causation criteria and the determination of drug exposure.

CIOMS full [concept note on Pharmacoepidemiology for Public Health](#)

You are invited to review and comment on the draft report entitled *Realising the Potential of Pharmacoepidemiology for Public Health Decision-Making*. [Download the report here](#).

Please note that comments will only be considered when using the [template provided here](#). The **deadline to submit your comments is 13 March 2026**.

* * * *

Contents [click to move among sections]

[:: Milestones, Perspectives](#)
[:: WHO](#)
[:: Organization Announcements](#)
[:: Journal Watch](#)
[:: Pre-Print Servers](#)

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

::::::

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *